| 查看: 1934 | 回复: 26 | ||
| 【奖励】 本帖被评价13次，作者xiaohezi7844增加金币 10.25 个 | ||
| 当前主题已经存档。 | ||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | ||
[资源]
The Art of Drug Synthesis
|
||
|
Contemporary Drug Synthesis 的姊妹篇 Publisher: Wiley-Interscience Number Of Pages: 276 Publication Date: 2007-07-09 Sales Rank: 286635 ISBN / ASIN: 0471752150 EAN: 9780471752158 Binding: Hardcover Manufacturer: Wiley-Interscience Studio: Wiley-Interscience The Art of Drug Synthesis illustrates how chemistry, biology, pharmacokinetics, and a host of other disciplines come together to produce successful medicines. The authors have compiled a collection of 21 representative categories of drugs, from which they have selected as examples many of the best-selling drugs on the market today. An introduction to each drug is provided, as well as background to the biology, pharmacology, pharmacokinetics, and drug metabolism, followed by a detailed account of the drug synthesis. Edited by prominent scientists working in drug discovery for Pfizer Meets the needs of a growing community of researchers in pharmaceutical R&D Provides a useful guide for practicing pharmaceutical scientists as well as a text for medicinal chemistry students An excellent follow-up to the very successful first book by these editors, Contemporary Drug Synthesis, but with all new therapeutic categories and drugs discussed. Foreword. Preface. Contributors. 1 THE ROLE OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY (John A. Lowe, III). 1.1 Introduction. 1.2 Hurdles in the Drug Discovery Process. 1.3 The Tools of Medicinal Chemistry. 1.3.1 In Silico Modeling. 1.3.2 Structure-Based Drug Design (SBDD). 1.4 The Role of Synthetic Chemistry in Drug Discovery. References. 2 PROCESS RESEARCH: HOW MUCH? HOW SOON? (Neal G. Anderson). 2.1 Introduction. 2.2 Considerations for Successful Scale-up to Tox Batches and Phase I Material. 2.3 Considerations for Phase 2 Material and Beyond. 2.3.1 Reagent Selection. 2.3.2 Solvent Selection. 2.3.3 Unit Operations. 2.3.4 Developing Simple, Effective, Efficient Work-ups and Isolations. 2.3.5 The Importance of Physical States. 2.3.6 Route Design and Process Optimization to Minimize COG. 2.4 Summary. References. I CANCER AND INFECTIOUS DISEASES. 3 AROMATASE INHIBITORS FOR BREAST CANCER: EXEMESTANE (AROMASIN), ANASTROZOLE (ARIMIDEX), AND LETROZOLE (FEMARA) (Jie Jack Li). 3.1 Introduction. 3.2 Synthesis of Exemestane. 3.3 Synthesis of Anastrozole. 3.4 Synthesis of Letrozole. References. 4 QUINOLONE ANTIBIOTICS: LEVOFLOXACIN (LEVAQUIN), MOXIFLOXACIN (AVELOX), GEMIFLOXACIN (FACTIVE), AND GARENOXACIN (T-3811) (Chris Limberakis). 4.1 Introduction. 4.1.1 Mechanism of Action. 4.1.2 Modes of Resistance. 4.1.3 Structure–Activity Relationship (SAR) and Structure–Toxicity Relationship (STR). 4.1.4 Pharmacokinetics. 4.1.5 Synthetic Approaches. 4.2 Levofloxacin. 4.3 Moxifloxacin. 4.4 Gemifloxacin. 4.5 Garenoxacin (T-3811): A Promising Clinical Candidate. References. 5 TRIAZOLE ANTIFUNGALS: ITRACONAZOLE (SPORANOX), FLUCONAZOLE (DIFLUCAN), VORICONAZOLE (VFEND), AND FOSFLUCONAZOLE (PRODIF) (Andrew S. Bell). 5.1 Introduction. 5.2 Synthesis of Itraconazole. 5.3 Synthesis of Fluconazole. 5.4 Synthesis of Voriconazole. 5.5 Synthesis of Fosfluconazole. References. 6 NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE INHIBITORS (Arthur Harms). 6.1 Introduction. 6.2 Synthesis of Nevirapine. 6.3 Synthesis of Efavirenz. 6.4 Synthesis of Delavirdine Mesylate. References. 7 NEURAMINIDASE INHIBITORS FOR INFLUENZA: OSELTAMIVIR PHOSPHATE (TAMIFLU) AND ZANAMIVIR (RELENZA) (Douglas S. Johnson and Jie Jack Li). 7.1 Introduction. 7.1.1 Relenza. 7.1.2 Tamiflu. 7.2 Synthesis of Oseltamivir Phosphate (Tamiflu). 7.3 Synthesis of Zanamivir (Relenza). References. II CARDIOVASCULAR AND METABOLIC DISEASES. 8 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONISTS FOR TYPE 2 DIABETES (Jin Li). 8.1 Introduction. 8.1.1 Insulin. 8.1.2 Sulfonylurea Drugs. 8.1.3 Meglitinides. 8.1.4 Biguanides. 8.1.5 Alpha-Glucosidase Inhibitors. 8.1.6 Thiazolidinediones. 8.2 Synthesis of Rosiglitazone. 8.3 Synthesis of Pioglitazone. 8.4 Synthesis of Muraglitazar. References. 9 ANGIOTENSIN AT1 ANTAGONISTS FOR HYPERTENSION (Larry Yet). 9.1 Introduction. 9.2 Losartan Potassium. 9.2.1 Introduction to Losartan Potassium. 9.2.2 Synthesis of Losartan Potassium. 9.3 Valsartan. 9.3.1 Introduction to Valsartan. 9.3.2 Synthesis of Valsartan. 9.4 Irbesartan. 9.4.1 Introduction to Irbesartan. 9.4.2 Synthesis of Irbesartan. 9.5 Candesartan Cilexetil. 9.5.1 Introduction to Candesartan Cilexetil. 9.5.2 Synthesis of Candesartan Cilexetil. 9.6 Olmesartan Medoxomil. 9.6.1 Introduction to Olmesartan Medoxomil. 9.6.2 Synthesis of Olmesartan Medoxomil. 9.7 Eprosartan Mesylate. 9.7.1 Introduction to Eprosartan Mesylate. 9.7.2 Synthesis of Eprosartan Mesylate. 9.8 Telmisartan. 9.8.1 Introduction to Telmisartan. 9.8.2 Synthesis of Telmisartan. References. 10 LEADING ACE INHIBITORS FOR HYPERTENSION (Victor J. Cee and Edward J. Olhava). 10.1 Introduction. 10.2 Synthesis of Enalapril Maleate. 10.3 Synthesis of Lisinopril. 10.4 Synthesis of Quinapril. 10.5 Synthesis of Benazepril. 10.6 Synthesis of Ramipril. 10.7 Synthesis of Fosinopril Sodium. References. 11 DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION (Daniel P. Christen). 11.1 Introduction. 11.2 Synthesis of Nifedipine (Adalatw). 11.3 Synthesis of Felodepine (Plendilw). 11.4 Synthesis of Amlodipine Besylate (Norvascw). 11.5 Synthesis of Azelnidipine (Calblockw). References. 12 SECOND-GENERATION HMG-CoA REDUCTASE INHIBITORS (Jeffrey A. Pfefferkorn). 12.1 Introduction. 12.2 Synthesis of Fluvastatin (Lescolw). 12.3 Synthesis of Rosuvastatin (Crestorw). 12.4 Synthesis of Pitavastatin (Livalow). References. 13 CHOLESTEROL ABSORPTION INHIBITORS: EZETIMIBE (ZETIA) (Stuart B. Rosenblum). 13.1 Introduction. 13.2 Discovery Path to Ezetimibe. 13.3 Synthesis of Ezetimibe (Zetia). References. III CENTRAL NERVOUS SYSTEM DISEASES. 14 DUAL SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SSNRIs) FOR DEPRESSION (Marta Piñeiro-Núñez) 14.1 Introduction. 14.2 Synthesis of Venlafaxine. 14.3 Synthesis of Milnacipran. 14.4 Synthesis of Duloxetine. References. 15 GABAA RECEPTOR AGONISTS FOR INSOMNIA: ZOLPIDEM (AMBIEN), ZALEPLON (SONATA), ESZOPICLONE (ESTORRA, LUNESTA), AND INDIPLON (Peter R. Guzzo). 15.1 Introduction. 15.2 Synthesis of Zolpidem. 15.3 Synthesis of Zaleplon. 15.4 Synthesis of Eszopiclone. 15.5 Synthesis of Indiplon. References. 16 a2d LIGANDS: NEURONTIN (GABAPENTIN) AND LYRICA (PREGABALIN) (Po-Wai Yuen). 16.1 Introduction. 16.2 Synthesis of Gabapentin. 16.3 Synthesis of Pregabalin. References. 17 APPROVED TREATMENTS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER: AMPHETAMINE (ADDERALL), METHYLPHENIDATE (RITALIN), AND ATOMOXETINE (STRATERRA) (David L. Gray). 17.1 Introduction. 17.1.1 Stimulant versus Nonstimulants. 17.2 Synthesis of Amphetamine. 17.2.1 Pharmacokinetic Properties of d- and l-Amphetamine. 17.2.2 Chiral Synthesis of Amphetamine. 17.3 Synthesis of Methylphenidate. 17.3.1 Methylphenidate Formulations. 17.3.2 Chiral Synthesis of Methylphenidate. 17.4 Synthesis of Atomoxetine. References. Index. 下载链接： http://rapidshare.com/files/56350607/Johns9780471752158.rar 上面的连接确实下不了，发的时候可以下 下面的你们看看可以下不：http://www.isload.com.cn/store/n8hwuu3jypimu 若有需要的请在下面回复写上你的邮箱到时候我会发给你！！！ [ Last edited by xiaohezi7844 on 2008-4-16 at 14:00 ] |
回复此楼» 猜你喜欢
求助求助
已经有0人回复
-
农业资源与环境、智慧农业专业本科生毕业论文课题选题求助
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有239人回复
-
人工智能赋能聚合物及复合材料模型应用与实践
已经有0人回复
-
各国和国际组织现行药典注射用水质量标准
已经有0人回复
-
求助用微谱数据库查询
已经有0人回复
-
计算化学与人工智能驱动的MOFs性能预测与筛选技术
已经有0人回复
-
研三实验求指导
已经有0人回复
-
金属材料多尺度计算模拟技术与应用：微观机理到宏观性能的集成工作
已经有0人回复
-
江西科技师范大学微生物天然药物老师介绍
已经有23人回复
-
【招聘】清北（济南）生物科技招聘AI制药研发计算人才
已经有8人回复
23楼2008-05-09 09:51:03
2楼2008-04-11 19:23:21
3楼2008-04-12 01:44:07
4楼2008-04-12 08:28:57
